Premium
Preventive Effectiveness of Implantable Cardioverter Defibrillator in Reducing Sudden Cardiac Death in the Chinese Population: A Multicenter Trial of ICD Therapy versus Non‐ICD Therapy
Author(s) -
HUA WEI,
NIU HONGXIA,
FAN XIAOHAN,
DING LIGANG,
XU YIZHOU,
WANG JING,
CHEN KEPING,
WANG FANGZHENG,
ZHANG SHU
Publication year - 2012
Publication title -
journal of cardiovascular electrophysiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.193
H-Index - 138
eISSN - 1540-8167
pISSN - 1045-3873
DOI - 10.1111/j.1540-8167.2012.02435.x
Subject(s) - medicine , implantable cardioverter defibrillator , sudden cardiac death , incidence (geometry) , population , guideline , cumulative incidence , mortality rate , sudden death , clinical trial , cohort , physics , environmental health , pathology , optics
Preventive Effectiveness of Implantable Cardioverter. Introduction : This prospective and multicenter trial of the implantable cardioverter‐defibrillator (ICD) aimed to evaluate the mortality rate (including sudden cardiac death [SCD]) and the efficacy of ICD in Chinese patients with high risk of sudden death.Methods and Results: This trial was conducted in 31 centers in China. We enrolled 497 patients who fulfilled Class I indication for ICD (2002 ACC/AHA/NASPE guideline). All patients were followed‐up at 3, 6, and 12 months. Clinical characteristics and echocardiographic parameters were collected at baseline and follow‐up; Kaplan–Meier survival analysis was performed. Among 497 enrolled patients with Class I indication of ICD therapy, 112 (22.5%) agreed to and received ICD implantation (ICD group). The remaining 385 patients who were not available for ICD therapy were designated as the non‐ICD group. During a mean follow‐up of 11 ± 3 months, there were a total of 38 deaths, 2 in the ICD group with a mortality of 1.8% and 36 in the non‐ICD group, with a mortality of 9.4% and 26 due to SCD. The overall survival rate was 93% at 3 months of follow‐up, 91% at 6 months, and 89% at 12 months, with an incidence of SCD of 5%, 7%, and 8% at 3, 6, and 12 months, respectively.Conclusions: In patients with Class I indication of ICD implantation, the total mortality and incidence of SCD were high. ICD therapy can effectively reduce the mortality in such patients. (J Cardiovasc Electrophysiol, Vol. 23, pp. S5‐S9, November 2012)